Department of Clinical Sciences, FARAH, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium.
Respiratory department, CHU Liège. Domaine universitaire du Sart Tilman, B35, 4000 Liège, Belgium.
Int J Mol Sci. 2017 Dec 16;18(12):2735. doi: 10.3390/ijms18122735.
This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF.
这篇综述重点探讨了肺部微生物组在特发性肺纤维化中的作用。尽管肺部历史上被认为是无菌的，但现在已经在健康和病理条件下的肺部中很好地记录了细菌群落。特发性肺纤维化 (IPF) 的研究表明，细菌负担增加和/或潜在致病性细菌的丰度增加可能会导致疾病进展、急性加重和死亡。最近的研究强调了肺部微生物组与 IPF 中先天免疫系统之间的相互作用，这进一步证明了宿主和环境相互作用在疾病发病机制中的作用。现有的发表数据表明，肺部微生物组可能通过抗生素治疗、针对致病生物的免疫接种或针对胃食管反流的治疗成为一种治疗靶点。总的来说，已发表的文献表明，肺部微生物组可能在未来成为一种预后生物标志物、治疗靶点，并/或为 IPF 的发病机制提供解释。
